Inhibition of SARS Coronavirus Infection in Vitro with Clinically Approved Antiviral Drugs

Emerging Infectious Diseases

Volumn 10, Issue 4, 2004, Pages 581-586

  Tan, Emily L C ^a   Ooi, Eng Eong ^b   Lin, Chin Yo ^a   Tan, Hwee Cheng ^b   Ling, Ai Ee ^c   Lim, Bing ^a   Stanton, Lawrence W ^a  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b NATIONAL ENVIRONMENT AGENCY   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ALPHAN1 INTERFERON; ALPHAN3 INTERFERON; AMANTADINE; ANTIVIRUS AGENT; BETA1A INTERFERON; FOSCARNET SODIUM; GANCICLOVIR; HUMAN LEUKOCYTE INTERFERON ALPHA; INDINAVIR; INTERFERON BETA SERINE; LAMIVUDINE; MULTIFERON; NELFINAVIR; NUCLEOSIDE ANALOG; OSELTAMIVIR; PROTEINASE INHIBITOR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR; ZIDOVUDINE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG SCREENING; IN VITRO STUDY; INFECTION PREVENTION; NONHUMAN; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VERO CELL; VIRUS CULTURE; VIRUS LOAD; VIRUS PLAQUE;

EID: 1842536303     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1004.030458     Document Type: Article

References (31)

1. World Health Organization. Acute respiratory syndrome in China-update 3: disease outbreak reported: Geneva: The Organization; 2003.
2. Lee N, Hui DH, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986-94.
3. Ksiazek TG, Erdman D, Goldsmith C, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-66.
4. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1977-85.
5. Severe acute respiratory syndrome (SARS) and coronavirus testing-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:297-302.
6. Peiris JSM, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361:1767-72.
7. Chan-Yeung M, Yu WC. Outbreak of severe acute respiratory syndrome in Hong Kong Special Administrative Region: case report. BMJ 2003;326:850-2.
8. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003;361:1773-8.
9. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348:1995-2005.
10. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76.
11. Lapinsky SE, Hawryluck L. ICU management of severe acute respiratory syndrome. Intensive Care Med 2003;29:870-5.
12. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:2801-9. Erratum in: JAMA 2003;290:334.
13. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:2801-9. Erratum in: JAMA 2003;290:334.
14. Driscoll JS. Antiviral drugs. Aldershot, UK: Ashgate Publishing Ltd; 2002.
15. Ruan YJ, Wei CL, Ee AL, Vega VB, Thoreau H, Su ST, et al. Comparative full length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003;361:1779-85. Erratum in: Lancet 2003;361:1832.
16. Ruan YJ, Wei CL, Ee AL, Vega VB, Thoreau H, Su ST, et al. Comparative full length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003;361:1779-85. Erratum in: Lancet 2003;361:1832.
17. Richmond JY, McKinney RW. Biosafety in microbiological and biomedical laboratories. 4th ed. Washington: U.S. Government Printing Office; 1999.
18. Al-Jabri AA, Wigg MD, Oxford JS. Initial in vitro screening of drug candidates for their potential antiviral activities. In: Mahy, BWJ, Kangro HO, editors. Virology methods manual. London: Academic Press Ltd; 1996. p. 293-356.
19. Huffman JH, Sidwell RW. Khare GP, Witkowski JT, Allen LM, Robins RK. In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole, ICN-1229) on deoxy-ribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother 1973;3:235-41.
20. Saganuma T, Ishida N. An evaluation of a new antiviral agent 'Virazole' against influenza virus infections. Tohoku J Exp Med 1973;110:405-6.
21. Morrey JD, Smee DF, Sidwell RW, Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res 2002;55:107-16.
22. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alpha2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis. N Engl J Med 1998;339:1493-9.
23. Poynard TP, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial for interferon alpha2b plus ribavirin. Lancet 1998;352:1426-32.
24. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha2b alone or in combination with ribavirin as initial treatment for hepatitis C. N Engl J Med 1998; 339:1485-92.
25. Turner RB, Felton A, Kosak K, Kelsey DK, Meschievitz CK. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. J Infect Dis 1986;154:443-7.
26. Higgins PG, Phillpotts RJ, Scott GM, Wallace J, Bernhardt LL, Tyrrell DA. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother 1983;24:713-5.
27. Tyrrell DA. The efficacy and tolerance of intranasal interferons: studies at the common cold unit. J Antimicrob Chemother 1986;18B:153-6.
28. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998;58:2489-99.
29. Lee CK, Bluyssen HA, Levy DE. Regulation of interferon alpha responsiveness by the duration of Janus kinase activity. J Biol Chem 1997;272:21872-7.
30. Weingartl HM, Derbyshire JB. Antiviral activity against transmissible gastroenteritis virus, and cytotoxicity, of natural porcine interferons alpha and beta. Can J Vet Res 1991;55:143-9.
31. Jordan LT, Derbyshire JB. Antiviral activity of interferon against transmissible gastroenteritis virus in cell culture and ligated intestinal segments in neonatal pigs. Vet Microbiol 1994;38:263-76.